Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.

about

Problematic smartphone use, nature connectedness, and anxiety.

P2860

Q50055153-E481C699-DEAB-497B-8712-A061EF1FE071

P2860

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.

Item

http://www.wikidata.org/entity/Q53739720

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Defining optimal cutoff value ...... ting in glioblastoma patients.

@en

Defining optimal cutoff value ...... ting in glioblastoma patients.

@nl

type

Item

label

Defining optimal cutoff value ...... ting in glioblastoma patients.

@en

Defining optimal cutoff value ...... ting in glioblastoma patients.

@nl

prefLabel

Defining optimal cutoff value ...... ting in glioblastoma patients.

@en

Defining optimal cutoff value ...... ting in glioblastoma patients.

@nl

P1476

Defining optimal cutoff value ...... ting in glioblastoma patients.

@en

P2093

Guoqiang Yuan

http://www.w3.org/2001/XMLSchema#string

Hang Yin

http://www.w3.org/2001/XMLSchema#string

Junqiang Dai

http://www.w3.org/2001/XMLSchema#string

Kejun Ma

http://www.w3.org/2001/XMLSchema#string

Liang Niu

http://www.w3.org/2001/XMLSchema#string

Wangning Zhou

http://www.w3.org/2001/XMLSchema#string

Xiaoqing Wang

http://www.w3.org/2001/XMLSchema#string

Yawen Pan

http://www.w3.org/2001/XMLSchema#string

Yinian Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Communicating accuracy of tests to general practitioners: a controlled study.

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma

Measuring the accuracy of diagnostic systems

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests.

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of

Use of likelihood ratios for comparisons of binary diagnostic tests: underlying ROC curves.

P2888

s11060-017-2433-9

P304

193-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-017-2433-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28516344

http://www.w3.org/2001/XMLSchema#string

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.

about

P2860

P2860

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698